ManpowerGroup Reports 2nd Quarter 2026 Results

ManpowerGroup posted Q2 2026 net earnings of $53.5M ($1.13/diluted), up sharply from a $67.1M loss and driven by $4.9B revenue (+8% y/y; +6% constant currency) plus gross profit growth and SG&A reductions. Adjusted EPS was $0.99, up 27% in constant currency, with EPS helped by $0.14 from the Jefferson Wells U.S. business sale (net cash proceeds of $88M) versus restructuring/liquidation items. Management guided Q3 diluted EPS to $0.96–$1.06 (includes ~$0.02 unfavorable currency impact and a 44% effective tax rate).

Analysis

MAN looks less like a simple staffing rebound and more like an operating-leverage reset: the market should focus on how much of the cost base has already been removed before any durable volume recovery. If revenue merely holds mid-single digits, incremental EBIT can expand sharply because SG&A is now a much smaller denominator; that makes the next 1-2 quarters the key window for multiple re-rating. The catch is that this is still a cyclical recovery, not evidence of a secular demand breakout.

The cleaner way to express the thesis is relative value. MAN’s improving mix into higher-value professional services and RPO/MSP should outgrow plain-vanilla temp staffing peers if labor demand keeps firming, while competitors with slower restructuring or more Europe-sensitive exposure should lag. Second-order beneficiaries include payroll, HR software, and staffing-tech vendors if management truly keeps converting labor into productivity gains; the risk is that AI headlines cannibalize low-end placement volumes before the company can monetize higher-value services.

The contrarian point is that the quarter may be the best-looking one in the cycle rather than the start of a straight line up: US revenue is still not showing a full-volume breakout, and the guidance embeds a sharp tax headwind that can cap near-term EPS upside. Cash remains thin after debt paydown, so the balance sheet is improving but not yet a driver of capital returns. If the next prints show revenue decelerating below low-single digits or operating margin failing to expand, the recovery narrative likely stalls fast.

Key Decisions for Investors

• Go long MAN on a 1-3 month horizon if the stock has not already repriced to a cyclical recovery multiple; target is continued EBIT margin expansion as SG&A leverage shows through. Falsify if next quarter revenue growth slips below low-single digits or EBIT margin fails to improve sequentially.
• Pair trade: long MAN / short RHI over the next 1-2 quarters. MAN has more obvious restructuring leverage and a cleaner path to operating margin recovery; the pair is designed to isolate execution rather than macro beta.
• Use any post-earnings pullback to buy MAN common or a modest call spread into the next print, sized for a 6-18 month thesis. Risk/reward is favorable if management sustains cost discipline, but the trade should be cut if guidance implies the tax drag or FX headwind is broadening.
• Watch a basket short in more economically sensitive staffing proxies if US hiring data rolls over: RHI, KFY, and ADEYY/ADEN. The thesis breaks if private payrolls and temp-help employment reaccelerate over the next 1-2 months.